How RDC 660 ensures diversified products and support for doctors in different diseases
Paula Scanapieco, a specialist in medical cannabis logistics, speaks on Deusa Cast about the importance of RDC 660, product quality, and the role of companies in providing reliable information to doctors and patients in Brazil
Published on 08/20/2025

Medical cannabis in Brazil: the role of RDC 660 and serious companies in patient care
Ensuring that cannabis-based medications reach patients on time goes far beyond compliance: it is a matter of care and responsibility. In the Brazilian market, serious companies have been structuring themselves to offer reliable and quality products, keeping up with the regulatory changes that are transforming the sector... these were some of the reflections from Deusa Cast, which featured the participation of three specialists discussing the advances and challenges of medical cannabis regulation in Brazil.
Paula Scanapieco, commercial manager at Mile Express, was one of our interviewees and mentioned that, with the growth of the Brazilian market, many companies emerged rapidly, but not all with a focus on quality.

Today, there is a natural maturation movement: those who remain in the market prioritize reliable suppliers. At Mile Express, Paula works with American partners who invest in research, produce excellent medications, and provide clear information to doctors.
“It is essential for doctors to understand what they are prescribing and for patients to receive safe and effective products. This bridge between industry and medicine makes all the difference in people's lives”, she commented.
Medical education as a care strategy
More than just transporting medications, many companies have been dedicated to educating healthcare professionals about the particularities of each imported product. Paula emphasized that shared knowledge about composition, efficacy, and safety is crucial to generate confidence and good clinical results.
RDC 660: maturation and safety
Speaking specifically about the resolution, Paula was emphatic: RDC 660 “ended a lot of wrong things” by requiring documentary and regulatory compliance. For her, the change forced the market to adapt to pharmaceutical standards, prioritizing serious medications, trustworthy partners, and transparent processes, consolidating a safer and more mature sector.
Want to hear Paula Scanapieco's complete speech and follow the exchange of ideas with Larissa Meneghel and Juliana Sousa about the future of medical cannabis in Brazil? Watch the full episode of Deusa Cast on our Youtube channel.